Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial
about
Artemisinin-resistant malaria: research challenges, opportunities, and public health implicationsEmergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal studyEndoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffoldEffects of artesunate on parasite recrudescence and dormancy in the rodent malaria model Plasmodium vinckeiEfficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trialDefining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approachPast and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventionsEvidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemetherBaseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis.The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread.Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial.Ex vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant Plasmodium falciparum isolates from Cambodia.Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT intervalIndependent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast AsiaObserving in real time the evolution of artemisinin resistance in Plasmodium falciparumEx Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance.How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali.Ex vivo drug sensitivity profiles of Plasmodium falciparum field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidine-rich protein-2 assayPharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia.Optimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of Plasmodium falciparum field isolates.Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa.Clinical Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria at the China-Myanmar BorderGenetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia.Early parasitological response following artemisinin-containing regimens: a critical review of the literature.Genetic evaluation of the performance of malaria parasite clearance rate metrics.Severe malaria in Battambang Referral Hospital, an area of multidrug resistance in Western-Cambodia: a retrospective analysis of cases from 2006-2009Direct comparison of the histidine-rich protein-2 enzyme-linked immunosorbent assay (HRP-2 ELISA) and malaria SYBR green I fluorescence (MSF) drug sensitivity tests in Plasmodium falciparum reference clones and fresh ex vivo field isolates from CambMultiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia.Evaluation of parasite subpopulations and genetic diversity of the msp1, msp2 and glurp genes during and following artesunate monotherapy treatment of Plasmodium falciparum malaria in Western Cambodia.Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives.Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malariaKnow your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics.Use of quantitative pharmacology tools to improve malaria treatments.Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells.Impact of Extended Duration of Artesunate Treatment on Parasitological Outcome in a Cytocidal Murine Malaria Model.Antiviral effects of artesunate on polyomavirus BK replication in primary human kidney cells.Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence.Multidrug-resistant malaria and the impact of mass drug administration.
P2860
Q21032532-F10A52B1-50CB-4037-A7EA-4D2DB80BAACAQ24598695-B682E7B3-EE0C-4C19-9FB3-53422D62A0A5Q28077102-FEAFB814-9975-48D8-96A4-61FEEE8510AAQ28477603-7F04A2A6-A133-4B93-B18D-4A6B92BE48BDQ28541521-410205D8-F385-460F-BCF1-7F184676BEA5Q28546794-BA138FDB-E35A-4B31-8743-75295DDF0613Q28646971-9330313A-9238-467E-AD86-9509AC3AD102Q29353565-20735F16-5E7D-4882-88F7-ECB0D1678891Q30995133-27E232AF-D620-4F39-8978-01769A5D087EQ33655603-576B85C4-42DE-4127-8AE1-21DF3CBEDDB0Q33772980-5A9CC8C7-B7D6-4432-AE91-B6ED83D46962Q34298916-2684093E-3816-4131-A968-B6E36208958CQ34298973-C21AA5D0-31AB-4AEC-9BCE-5BE9D95FB8D8Q35102586-28CED75E-5BDA-46C3-A2FC-0688819E6D87Q35608785-AC5D2A29-FCFD-4DA9-A733-2663A8E324F6Q35859975-C77F46A6-D716-4B71-8900-0CD9BC302F54Q36076111-49FF5FEC-4DAA-45BB-8805-E4C355E0630EQ36080109-DC3912E2-430F-4960-A7F7-E6791C53FB17Q36112839-FC76206C-68A3-47E2-9E56-A29EF2C1B572Q36364184-7AA07B8C-611D-4EA5-B62A-A09C071D6B60Q36372815-F568EB19-A0E9-4832-8898-2D0B5EC9C404Q36439747-4C277C1E-9E92-4F54-81A9-A76B3FD3609FQ36485224-D57D149D-1463-4CB2-AE73-E0032004E105Q36512312-52BA6081-3E3D-468B-8CA6-062F09E0623CQ36831456-405671B3-2581-4F85-8F8E-ABF612AB3485Q36936359-A6754BC4-1EB6-4256-B275-F2C8805DFF2AQ36975989-9FB7B70E-AE62-458A-ACA9-FBAA37EC84BAQ37028482-692E072B-CC6A-4F52-AA8D-15DC82185F10Q37253966-3A955AA3-E13D-447E-BD84-4AECFB3A2A92Q37315145-FF1D3EE6-7A13-46BA-AF5C-4089BC820245Q37348232-1A44442E-3668-4361-B619-B462378A3193Q37539183-F37F099E-C058-4633-863B-CFD88654B0C0Q37979631-1188B39C-6EB6-4885-9192-1547834DDA48Q38664529-1687E5F2-4395-4703-BC8F-629AF56CB662Q38962966-76C9009A-D9BF-4DE6-B6F6-E92CD3C8A51EQ41695336-0D0D4198-4FAA-4DEF-A465-3213CE691211Q41907468-777C4646-A5DC-4B18-A284-39C0592ABEAAQ43923927-72216F07-AB8B-4538-B210-AB42C8921FB6Q53702249-DA098C50-53A3-43A2-9F28-84C8230B5FC6
P2860
Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Artesunate dose escalation for ...... e: a randomized clinical trial
@ast
Artesunate dose escalation for ...... e: a randomized clinical trial
@en
Artesunate dose escalation for ...... e: a randomized clinical trial
@nl
type
label
Artesunate dose escalation for ...... e: a randomized clinical trial
@ast
Artesunate dose escalation for ...... e: a randomized clinical trial
@en
Artesunate dose escalation for ...... e: a randomized clinical trial
@nl
prefLabel
Artesunate dose escalation for ...... e: a randomized clinical trial
@ast
Artesunate dose escalation for ...... e: a randomized clinical trial
@en
Artesunate dose escalation for ...... e: a randomized clinical trial
@nl
P2093
P2860
P921
P3181
P1433
P1476
Artesunate dose escalation for ...... e: a randomized clinical trial
@en
P2093
Ans Timmermans
Bryan Smith
Chanthap Lon
David Saunders
Delia Bethell
Duong Socheat
Jessica Lin
Kurt Schaecher
Mark M Fukuda
Paktiya Teja-Isavadharm
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0019283
P407
P577
2011-01-01T00:00:00Z